GlaxoSmithKline Plc’s drug for a rare, often deadly form of cancer won the backing of U.S. advisers, while a similar treatment from Merck & Co. and Ariad Pharmaceuticals Inc. failed to gain support.
Amgen Inc., the world’s biggest biotechnology company, failed to win the backing of a U.S. advisory panel for its drug to delay tumors spreading to bones in patients with advanced prostate cancer.
Affymax Inc. surged the most in 16 months after winning a U.S. advisory panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson.
"This is an unmet need in a group that has really run out of options."
- Wyndham Wilson on Jun 20, 2012